Vaxart, Inc.
NASDAQ:VXRTBiotechnology
Healthcare
$0.53 -1.75%
-$0.01 today
- Market cap
- $129.30M
- Beta
- 1.09
- P/E (TTM)
- 3.6
- EPS (TTM)
- $0.15
52W Low $0.26High $0.84
Volume 0.12M
Average 0.41M
Income Statement
Follow revenue through to earnings.
Revenue
$237.26M
FY 2025 · Annual
+726.7% YoYOperating Income
$18.07M
FY 2025 · Annual
Net Income
$16.33M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 892K | 107K | 7.38M | 28.7M | 237.26M |
| Cost of Revenue | 48.75M | 0 | 4.5M | 0 | 0 |
| Gross Profit | (47.86M) | 107K | 2.88M | 28.7M | 237.26M |
| Gross Margin | -5365.1% | 100.0% | 39.0% | 100.0% | 100.0% |
| Research & Development | 48.75M | 81.05M | 68.14M | 74.21M | 201.58M |
| Selling, General & Admin | 21.89M | 29.39M | 22.58M | 20.78M | 17.61M |
| Operating Expenses | 24.9M | 114.69M | 86.23M | 94.99M | 219.18M |
| Depreciation & Amortization | 2.43M | 5.81M | 8.62M | 8.85M | 8.58M |
| EBITDA | (66.45M) | (100.58M) | (72.13M) | (54.87M) | 28.21M |
| EBITDA Margin | -7449.7% | -94000.9% | -977.5% | -191.2% | 11.9% |
| Operating Income | (72.75M) | (114.59M) | (83.35M) | (66.29M) | 18.07M |
| Operating Margin | -8156.1% | -107090.7% | -1129.5% | -231.0% | 7.6% |
| Interest Income | 81K | 1.25M | 2.65M | 2.54M | 1.6M |
| Interest Expense | 1.48M | 1.31M | 1.45M | 2.97M | 2.82M |
| Other Income / Expenses | 2.39M | 6.9M | 1.14M | (395K) | (1.27M) |
| Income Before Tax | (70.36M) | (107.69M) | (82.2M) | (66.69M) | 16.8M |
| Pre-Tax Margin | -7888.2% | -100645.8% | -1114.0% | -232.4% | 7.1% |
| Income Tax Expense | 107K | 67K | 261K | 260K | 476K |
| Net Income | (70.47M) | (107.76M) | (82.47M) | (66.95M) | 16.33M |
| Net Margin | -7900.2% | -100708.4% | -1117.6% | -233.3% | 6.9% |
| EPS (Basic) | (0.14) | (0.22) | (0.17) | (0.14) | 0.07 |
| EPS (Diluted) | (0.14) | (0.22) | (0.17) | (0.14) | 0.07 |
| 487.26M | 487.26M | 487.26M | 487.26M | 230.27M | |
| 487.26M | 487.26M | 487.26M | 487.26M | 230.35M |
VXRT Earnings Waterfall · TTM
NASDAQ:VXRT · Revenue to Net Income
Key Ratios
EPS$0.14
Gross Margin100.0%
Net Margin4.3%
P/E Ratio0.8
P/S Ratio2.1
Analysis
$255.6M of revenue converted into $37.1M of net income for the selected period. Gross margin is 100.0% and net margin is 4.3%, showing how much revenue survives after costs and taxes. EPS is $0.14, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| DEFA14A | DEFA14A filing | Jul 2, 2026 | |
| 8-K | Current report | Jul 2, 2026 | |
| DFAN14A | DFAN14A filing | Jul 2, 2026 | |
| DEFA14A | DEFA14A filing | Jul 1, 2026 | |
| 8-K | Current report | Jun 26, 2026 |
How much revenue does VXRT generate?
Vaxart, Inc. (VXRT) reported $237.26M of revenue in fiscal 2025.
Is VXRT profitable?
Vaxart, Inc. (VXRT) reported $16.33M of net income, with a net margin of 6.9%.
Continue the stock analysis
Jump to another research area for this company.